Birth defects a concern, but cardio may dominate Qnexa's 2nd FDA panel
This article was originally published in Scrip
Executive Summary
Investors did not lose heart on 17 February in hopes that Vivus still has a chance to obtain US approval of its experimental combination weight-loss pill Qnexa (phentermine/topiramate), despite concerns again raised by the US FDA over the potential of birth defects and adverse cardiovascular effects linked with the product in clinical testing.